Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7086-7097

  Tsiang, Manuel ^a   Jones, Gregg S ^a   Goldsmith, Joshua ^a   Mulato, Andrew ^a   Hansen, Derek ^a   Kan, Elaine ^a   Tsai, Luong ^a   Bam, Rujuta A ^a   Stepan, George ^a   Stray, Kirsten M ^a   Niedziela Majka, Anita ^a   Yant, Stephen R ^a   Yu, Helen ^a   Kukolj, George ^a   Cihlar, Tomas ^a   Lazerwith, Scott E ^a   White, Kirsten L ^a   Jin, Haolun ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICTEGRAVIR; DARUNAVIR; DOLUTEGRAVIR; ELVITEGRAVIR; EMTRICITABINE; RALTEGRAVIR; TENOFOVIR; TENOFOVIR ALAFENAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; FUSED HETEROCYCLIC RINGS; INTEGRASE; INTEGRASE INHIBITOR; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CC50; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; EC50; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IC50; IN VITRO STUDY; MACROPHAGE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS MUTANT; VIRUS MUTATION; VIRUS RECOMBINANT; CELL LINE; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MUTATION;

ANTI-HIV AGENTS; CELL LINE; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; HETEROCYCLIC COMPOUNDS, 3-RING; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MUTATION; RALTEGRAVIR POTASSIUM;

EID: 84996488595     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01474-16     Document Type: Article

References (56)

1. Hazuda DJ. 2012. HIV integrase as a target for antiretroviral therapy. Curr Opin HIV AIDS 7:383-389. http://dx.doi.org/10.1097/COH.0b013e3283567309.
2. Powderly WG. 2010. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrob Chemother 65:2485-2488. http://dx.doi.org/10.1093/jac/dkq350.
3. Messiaen P, Wensing AM, Fun A, Nijhuis M., Brusselaers N, Vandekerckhove L. 2013. Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis. PLoS One 8:e52562. http://dx.doi.org/10.1371/journal.pone.0052562.
4. Cooper DA, Steigbigel RT, Gatell J, Rockstroh J., Katlama C, Yeni P, Lazzarin A., Clotet B, Kumar P, Eron J.E., Schechter M., Markowitz M, Loutfy MR, Lennox J.L., Zhao J., Chen J, Ryan DM, Rhodes R.R., Killar JA, Gilde LR, Strohmaier KM, Meibohm A.R., Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen B. 2008. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 359:355-365. http://dx.doi.org/10.1056/NEJMoa0708978.
5. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F., Ratanasuwan W, Kovacs C, Prada G., Morales-Ramirez JO, Crumpacker CS, Isaacs R.D., Campbell H., Strohmaier KM, Wan H, Danovich RM, Teppler H. 2009. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 52:350-356. http://dx.doi.org/10.1097/QAI.0b013e3181b064b0.
6. Steigbigel RT, Cooper DA, Kumar P.N., Eron JE, Schechter M, Markowitz M, Loutfy M.R., Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P., Lazzarin A, Clotet B, Zhao J., Chen J, Ryan DM, Rhodes R.R., Killar JA, Gilde LR, Strohmaier KM, Neibohm A.R., Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Teppler H. 2008. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 359:339-353. http://dx.doi.org/10.1056/NEJMoa0708975.
7. Shimura K, Kodama EN 2009. Elvitegravir: a new HIV integrase inhibitor. Antivir Chem Chemother 20:79-85. http://dx.doi.org/10.3851/IMP1397.
8. Zolopa AR, Berger DS, Lampiris H, Zhong L., Chuck SL, Enejosa JV, Kearney BP, Cheng AK 2010. Activity of elvitegravir, a once-daily integrase inhibitor, against resistant HIV type 1: results of a phase 2, randomized, controlled, dose-ranging clinical trial. J Infect Dis 201:814-822. http://dx.doi.org/10.1086/650698.
9. Xu L, Liu H, Hong A., Vivian R, Murray BP, Callebaut C, Choi Y.C., Lee MS, Chau J, Tsai LK, Stray K.M., Strickley RG, Wang J, Tong L, Swaminathan S., Rhodes GR, Desai MC. 2014. Structure-activity relationships of diamine inhibitors of cytochrome P450 (CYP) 3A as novel pharmacoenhancers. Part II. P2/P3 region and discovery of cobicistat (GS-9350). Bioorg Med Chem Lett 24:995-999.
10. Hazuda DJ, Anthony NJ, Gomez R.P., Jolly SM, Wai JS, Zhuang L, Fisher T.E., Embrey M., Guare JP, Jr, Egbertson MS, Vacca JP, Huff JR, Felock PJ, Witmer MV, Stillmock KA, Danovich R, Grobler J, Miller MD, Espeseth AS, Jin L, Chen IW, Lin JH, Kassahun K, Ellis JD, Wong BK, Xu W, Pearson PG, Schleif WA, Cortese R, Emini E, Summa V, Holloway MK, Young SD. 2004. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci U S A 101:11233-11238. http://dx.doi.org/10.1073/pnas.0402357101.
11. Garrido C, Villacian J, Zahonero N., Pattery T, Garcia F, Gutierrez F., Caballero E, Van Houtte M, Soriano V, de Mendoza C. 2012. Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. Antimicrob Agents Chemother 56: 2873-2878. http://dx.doi.org/10.1128/AAC.06170-11.
12. Malet I, Delelis O, Valantin M.A., Montes B., Soulie C, Wirden M, Tchertanov L., Peytavin G, Reynes J, Mouscadet J.F., Katlama C., Calvez V, Marcelin AG. 2008. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 52:1351-1358. http://dx.doi.org/10.1128/AAC.01228-07.
13. Mesplede T, Quashie PK, Wainberg MA 2012. Resistance to HIV integrase inhibitors. Curr Opin HIV AIDS 7:401-408. http://dx.doi.org/10.1097/COH.0b013e328356db89.
14. Geretti AM, Armenia D, Ceccherini-Silberstein F. 2012. Emerging patterns and implications of HIV-1 integrase inhibitor resistance. Curr Opin Infect Dis 25:677-686. http://dx.doi.org/10.1097/QCO.0b013e32835a1de7.
15. Wainberg MA, Mesplede T, Quashie PK 2012. The development of novel HIV integrase inhibitors and the problem of drug resistance. Curr Opin Virol 2:656-662. http://dx.doi.org/10.1016/j.coviro.2012.08.007.
16. Min S, Song I, Borland J., Chen S, Lou Y, Fujiwara T., Piscitelli SC. 2010. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 54:254-258. http://dx.doi.org/10.1128/AAC.00842-09.
17. Kobayashi M, Yoshinaga T, Seki T., Wakasa-Morimoto C, Brown KW, Ferris R, Foster S.A., Hazen RJ, Miki S, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T., Kawasuji T, Johns BA, Underwood M.R., Garvey EP, Sato A, Fujiwara T. 2011. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 55:813-821. http://dx.doi.org/10.1128/AAC.01209-10.
18. Lenz JC, Rockstroh JK 2011. S/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin Investig Drugs 20:537-548. http://dx.doi.org/10.1517/13543784.2011.562189.
19. Karmon SL, Markowitz M. 2013. Next-generation integrase inhibitors: where to after raltegravir? Drugs 73:213-228. http://dx.doi.org/10.1007/s40265-013-0015-5.
20. Raffi F, Jaeger H, Quiros-Roldan E, Albrecht H., Belonosova E, Gatell JM, Baril J.G., Domingo P., Brennan C, Almond S, Min S. 2013. Oncedaily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Lancet Infect Dis 13:927-935. http://dx.doi.org/10.1016/S1473-3099(13)70257-3.
21. Cahn P, Pozniak AL, Mingrone H, Shuldyakov A., Brites C, Andrade-Villanueva JF, Richmond G, Buendia C.B., Fourie J., Ramgopal M, Hagins D, Felizarta F., Madruga J, Reuter T, Newman T., Small CB, Lombaard J, Grinsztejn B, Dorey D., Underwood M, Griffith S, Min S. 2013. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 382:700-708. http://dx.doi.org/10.1016/S0140-6736(13)61221-0.
22. Clotet B, Feinberg J, van Lunzen J, Khuong-Josses MA, Antinori A., Dumitru I, Pokrovskiy V, Fehr J., Ortiz R, Saag M, Harris J., Brennan C, Fujiwara T, Min S. 2014. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study. Lancet 383:2222-2231. http://dx.doi.org/10.1016/S0140-6736(14)60084-2.
23. Walmsley SL, Antela A, Clumeck N., Duiculescu D, Eberhard A, Gutierrez F., Hocqueloux L, Maggiolo F, Sandkovsky U., Granier C, Pappa K, Wynne B., Min S, Nichols G. 2013. Dolutegravir plus abacavirlamivudine for the treatment of HIV-1 infection. N Engl J Med 369:1807-1818. http://dx.doi.org/10.1056/NEJMoa1215541.
24. Eron JJ, Clotet B, Durant J., Katlama C, Kumar P, Lazzarin A., Poizot-Martin I, Richmond G, Soriano V., Ait-Khaled M, Fujiwara T, Huang J., Min S, Vavro C, Yeo J. 2013. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING study. J Infect Dis 207:740-748. http://dx.doi.org/10.1093/infdis/jis750.
25. Lepik KJ, Yip B, Robbins M., Woods C, Lima VD, McGovern R.A., Zhang WW, Barrios R, Montaner JSG, Harrigan PR. 2016. Prevalence and incidence of integrase drug resistance in BC, Canada 2009-2015. Abstr 23rd Conf Retroviruses Opportunistic Infect, abstr 492LB.
26. Castagna A, Maggiolo F, Penco G., Wright D, Mills A, Grossberg R., Molina JM, Chas J, Durant J, Moreno S., Doroana M, Ait-Khaled M, Huang J, Min S., Song I, Vavro C, Nichols G., Yeo JM. 2014. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study. J Infect Dis 210:354-362. http://dx.doi.org/10.1093/infdis/jiu051.
27. Koteff J, Borland J, Chen S., Song I, Peppercorn A, Koshiba T., Cannon C, Muster H, Piscitelli SC 2013. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and paraaminohippurate clearance in healthy subjects. Br J Clin Pharmacol 75: 990-996. http://dx.doi.org/10.1111/j.1365-2125.2012.04440.x.
28. ViiV Healthcare. 2015. Tivicay 50 mg film-coated tablets. ViiV Healthcare, Middlesex, United Kingdom.
29. Kafri T, van Praag H, Ouyang L, Gage F.H., Verma IM. 1999. A packaging cell line for lentivirus vectors. J Virol 73:576-584.
30. Butler SL, Hansen MS, Bushman FD 2001. A quantitative assay for HIV DNA integration in vivo. Nat Med 7:631-634. http://dx.doi.org/10.1038/87979.
31. Cihlar T, Ray AS, Boojamra C.G., Zhang L., Hui H, Laflamme G, Vela J.E., Grant D., Chen J, Myrick F, White K.L., Gao Y., Lin KY, Douglas JL, Parkin NT, Carey A, Pakdaman R., Mackman RL. 2008. Design and profiling of GS-9148, a novel nucleotide analog active against nucleosideresistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131 Antimicrob Agents Chemother 52:655-665.
32. Cihlar T, He GX, Liu X, Chen J.M., Hatada M., Swaminathan S, McDermott MJ, Yang Z.Y., Mulato AS, Chen X, Leavitt SA, Stray K.M., Lee WA. 2006. Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring. J Mol Biol 363:635-647. http://dx.doi.org/10.1016/j.jmb.2006.07.073.
33. Jones GS, Yu F, Zeynalzadegan A., Hesselgesser J, Chen X, Chen J., Jin H, Kim CU, Wright M, Geleziunas R., Tsiang M. 2009. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 53:1194-1203. http://dx.doi.org/10.1128/AAC.00984-08.
34. Wang Y, Klock H, Yin H., Wolff K, Bieza K, Niswonger K., Matzen J, Gunderson D, Hale J., Lesley S, Kuhen K, Caldwell J., Brinker A. 2005. Homogeneous high-throughput screening assays for HIV-1 integrase 3beta-processing and strand transfer activities. J Biomol Screen 10:456-462. http://dx.doi.org/10.1177/1087057105275212.
35. Tsiang M, Jones GS, Niedziela-Majka A, Kan E., Lansdon EB, Huang W, Hung M, Samuel D., Novikov N, Xu Y, Mitchell M., Guo H, Babaoglu K, Liu X., Geleziunas R, Sakowicz R. 2012. New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 287:21189-21203. http://dx.doi.org/10.1074/jbc.M112.347534.
36. Lazerwith SE, Cai R, Chen X., Desai MC, Eng S, Jacques R, Ji M., Martin H, McMahon C, Mish M., Morganelli P, Mwangi J, Pyun H.J., Schmitz U., Stepan G, Szwarcberg J, Tang J., Tsiang M, Wang J, White K., Wiser L, Zack J, Jin H. 2016. Discovery of bictegravir (GS-9883), a novel, unboosted, once-daily HIV-1 integrase strand transfer inhibitor (INSTI) with improved pharmacokinetics and in vitro resistance profile. ASM Microbe 2016, poster 414.
37. Shimura K, Kodama E, Sakagami Y., Matsuzaki Y, Watanabe W, Yamataka K., Watanabe Y, Ohata Y, Doi S., Sato M, Kano M, Ikeda S., Matsuoka M. 2008. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137). J Virol 82:764-774. http://dx.doi.org/10.1128/JVI.01534-07.
38. Prichard MN, Shipman C, Jr. 1990. A three-dimensional model to analyze drug-drug interactions. Antiviral Res 14:181-205. http://dx.doi.org/10.1016/0166-3542(90)90001N.
39. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
40. Quashie PK, Mesplede T, Wainberg MA 2013. Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 26:43-49.
41. Quashie PK, Mesplede T, Han Y.S., Oliveira M., Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA 2012. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 86:2696-2705. http://dx.doi.org/10.1128/JVI.06591-11.
42. Pozniak A, Mingrone H, Shuldyakov A., Brites C, Andrade-Villanueva JF, Hagins D, Buendia C.B., Dorey D., Griffith S, Min S. Dolutegravir (DTG) versus raltegravir (RAL) in ART-experienced, integrase-naive subjects: 24 week interim results from SAILING (ING111762). Abstr 20th Conf Retroviruses Opportunistic Infect, abstr 179LB.
43. Lataillade M, Chiarella J, Kozal MJ 2007. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Antivir Ther 12:563-570.
44. Jones G, Ledford RM, Yu F, Chen X., Miller MD, Tsiang M, McColl DJ. In vitro resistance profile of HIV-1 mutants selected by the HIV-1 integrase inhibitor, GS-9137 (JTK-303). Abstr 14th Conf Retroviruses Opportunistic Infect, abstr 627.
45. Margot NA, Hluhanich RM, Jones G.S., Andreatta KN, Tsiang M, McColl DJ, White K.L., Miller MD. 2012. In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4. Antiviral Res 93:288-296. http://dx.doi.org/10.1016/j.antiviral.2011.12.008.
46. Wares M, Mesplede T, Quashie P.K., Osman N., Han Y, Wainberg MA. 2014. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology 11:7. http://dx.doi.org/10.1186/1742-4690-11-7.
47. Hachiya A, Ode H, Matsuda M., Kito Y, Shigemi U, Matsuoka K., Imamura J, Yokomaku Y, Iwatani Y., Sugiura W. 2015. Natural polymorphism S119R of HIV-1 integrase enhances primary INSTI resistance. Antiviral Res 119:84-88. http://dx.doi.org/10.1016/j.antiviral.2015.04.014.
48. McColl DJ, Chen X. 2010. Strand transfer inhibitors of HIV-1 integrase: bringing IN a new era of antiretroviral therapy. Antiviral Res 85:101-118. http://dx.doi.org/10.1016/j.antiviral.2009.11.004.
49. Abram M, Margot N, Barnes T., Ram R, Chen X, White K., Miller M, Callebaut C. 2014. Clinical impact and characterization of HIV integrase inhibitor resistance associated with T97A: a low-level polymorphic integrase mutation, abstr POH-017. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.
50. Maertens GN, Hare S, Cherepanov P. 2010. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 468: 326-329. http://dx.doi.org/10.1038/nature09517.
51. Serrao E, Krishnan L, Shun M.C., Li X., Cherepanov P, Engelman A, Maertens GN 2014. Integrase residues that determine nucleotide preferences at sites of HIV-1 integration: implications for the mechanism of target DNA binding. Nucleic Acids Res 42:5164-5176. http://dx.doi.org/10.1093/nar/gku136.
52. White KL, Kulkarni R, McColl D.J., Rhee MS, Szwarcberg J, Cheng AK, Miller MD 2015. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients. Antivir Ther 20:317-327.
53. Kulkarni R, Abram ME, McColl D.J., Barnes T., Fordyce MW, Szwarcberg J, Cheng AK, Miller M.D., White KL. 2014. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus atazanavir+ritonavir+emtricitabine/tenofovir DF in antiretroviral-naive patients. HIV Clin Trials 15:218-230. http://dx.doi.org/10.1310/hct1504-218.
54. Hurt CB, Sebastian J, Hicks C.B., Eron JJ. 2014. Resistance to HIV integrase strand transfer inhibitors among clinical specimens in the United States, 2009-2012. Clin Infect Dis 58:423-431. http://dx.doi.org/10.1093/cid/cit697.
55. Huang W, Frantzell A, Fransen S., Petropoulos CJ. 2013. Multiple genetic pathways involving amino acid position 143of HIV-1 integrase are preferentially associated with specific secondary amino acid substitutions and confer resistance to raltegravir and cross-resistance to elvitegravir. Antimicrob Agents Chemother 57:4105-4113. http://dx.doi.org/10.1128/AAC.00204-13.
56. Mesplede T, Quashie PK, Osman N, Han Y., Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA 2013. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 10: 22. http://dx.doi.org/10.1186/1742-4690-10-22.